Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

The neoadjuvant/adjuvant pembrolizumab and chemotherapy combination was approved by the FDA in October 2023 for use in this patient population.

Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC

Zongertinib demonstrated durable efficacy in patients with pretreated advanced HER2-mutant non–small cell lung cancer.

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC 

Second-line lenvatinib had clinically meaningful efficacy in patients with advanced HCC after progression on atezolizumab plus bevacizumab.

Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab

The phase 3 TROPiCS-04 study missed its primary end point of improved OS with sacituzumab govitecan vs chemotherapy in patients with urothelial cancer.

Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

Articles

The FDA awards accelerated approval to encorafenib regimen in BRAF V600E+ CRC, ensartinib wins approval in ALK+ non–small cell lung cancer, and more.

The OncFive: Top Oncology Articles for the Week of 12/15


Gina Mauro is your lead editorial contact for 

. She joined the company in 2015 and has held various positions on 

; she is also the on-air correspondent for 

. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com 

 
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages 

 social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: 

Adding dostarlimab to chemotherapy and niraparib maintenance improved progression-free survival in first-line advanced ovarian cancer.

Addition of Dostarlimab to Chemo and Niraparib Maintenance Boosts PFS in Advanced Ovarian Cancer

 as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: 

The addition of pegcrisantaspase to venetoclax may overcome resistance to prior BCL-2 inhibitor–based regimens for patients with relapsed/refractory AML. 

Venetoclax Plus PegC May Overcome Resistance to Prior BCL-2 Inhibitors in R/R AML 

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

Assessing Liver Function in Patients with HCC

Videos

Experts discuss the assessment of liver function in patients with hepatocellular carcinoma (HCC) while considering key data from recent clinical trials.

Rachna Shroff, MD, MS, FASCO, discusses hepatocellular carcinoma, noting its rising global incidence and identifying underlying liver cirrhosis as a key risk factor influenced by conditions like viral hepatitis and fatty liver disease; diagnosis often involves radiographic imaging and triple-phase CT and MRI scans, while treatment necessitates a multidisciplinary approach involving hepatologists, surgeons, and other specialists.

Risk Factors of Hepatocellular Carcinoma (HCC)

Drs Vogel and Singal discuss the critical importance of assessing liver function in hepatocellular carcinoma patients, as it impacts prognosis and treatment strategies; they mention the evolution from Child-Pugh scoring to the ALBI score, which uses albumin and bilirubin levels, for a more objective evaluation of liver health.

Importance of Assessing Liver Function in HCC

The ALBI score, originally developed to stratify cirrhotic patients undergoing resection, has evolved into a vital tool for assessing prognosis and treatment efficacy in various stages of hepatocellular carcinoma and is now being explored for its utility in other liver-related diseases.

Assessing Liver Function in Patients With HCC: The ALBI Score

Arndt Vogel, MD, explains that the Child-Pugh score, although simpler to calculate than the ALBI score, sometimes lacks granularity in assessing liver function in hepatocellular carcinoma patients; however, both scoring systems are considered valuable tools in clinical settings and trials for evaluating liver function's prognostic impact on treatment outcomes.

Assessing Liver Function in Patients With HCC: The Child-Pugh Score

Rachna Shroff, MD, MS, FASCO, and Amit Singal, MD, discuss the use of various liver function assessment scores—Child-Pugh, ALBI, and MELD—in the care of patients with hepatocellular carcinoma, emphasizing their pros, cons, and roles in treatment decision-making.

Assessing Liver Function in Patients With HCC: The MELD Score

Arndt Vogel, MD, discusses the post-hoc analyses of two key clinical trials focusing on the impact of liver function, measured by ALBI and Child-Pugh scores, on outcomes in hepatocellular carcinoma treatments.

Updates in First-Line Systemic Therapy for Patients With HCC

Amit Singal, MD, reviews analyses of the HIMALAYA and KEYNOTE-240 trials, focusing on the impact of liver function via ALBI grades on treatment outcomes and safety in patients with hepatocellular carcinoma.

Key Outcomes Data in Patients With HCC Based on Liver Function

Rachna Shroff, MD, MS, FASCO, shares data from the CARES-310 study showing improved progression-free and overall survival in patients with hepatocellular carcinoma treated with camrelizumab and rivoceranib compared to sorafenib, regardless of liver function.

Rivoceranib plus Camrelizumab for First-Line Treatment of HCC: Data from CARES-310

Experts emphasize the importance of using multiple liver function assessments for more comprehensive patient evaluation in hepatocellular carcinoma treatment.

Importance of Assessing Liver Function in HCC

EP: 1.Risk Factors of Hepatocellular Carcinoma (HCC)

EP: 2.Importance of Assessing Liver Function in HCC

EP: 3.Assessing Liver Function in Patients With HCC: The ALBI Score

EP: 4.Assessing Liver Function in Patients With HCC: The Child-Pugh Score

EP: 5.Assessing Liver Function in Patients With HCC: The MELD Score

EP: 6.Updates in First-Line Systemic Therapy for Patients With HCC

EP: 7.Key Outcomes Data in Patients With HCC Based on Liver Function

EP: 8.Rivoceranib plus Camrelizumab for First-Line Treatment of HCC: Data from CARES-310

EP: 9.The Future of Liver Function Assessments in HCC

Latest Conference Coverage